McNeil Nicotrol NS nasal spray switch may be reviewed at NDAC/Drug Abuse meeting.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL NICOTROL NS NASAL SPRAY Rx-TO-OTC SWITCH COULD BE TOPIC of discussion at a joint meeting of FDA's Nonprescription Drugs and Drug Abuse Advisory Committees scheduled for July 27. The joint session will be held on the first day of a three-day meeting marathon for NDAC; the date has been slated for discussion of a new drug application.